As 2026 unfolds, several patent cases are poised to significantly influence the legal landscape, particularly in the pharmaceutical and technology sectors. Legal professionals should closely monitor the following developments:
-
GlaxoSmithKline Biologicals SA et al. v. Moderna, Inc. et al.
Initiated in October 2024, this case involves GlaxoSmithKline (GSK) alleging that Moderna’s mRESVIA RSV F protein mRNA vaccine infringes on multiple GSK patents. The litigation is progressing in the District of Delaware, with fact discovery scheduled to conclude by July 29, 2026, and a jury trial set for July 19, 2027. The outcome could have significant implications for mRNA vaccine patent rights and the broader pharmaceutical industry.
-
Apple Watch Health Monitoring Patent Dispute
Apple Inc. faces ongoing litigation with Masimo Corporation over alleged patent infringements related to health monitoring technologies in Apple Watches. In November 2025, a federal jury awarded Masimo $634 million, finding that Apple had infringed on Masimo’s pulse oximetry patents. Apple has announced plans to appeal the decision. This case underscores the complexities of integrating health technologies into consumer devices and the potential for substantial financial repercussions.
-
Inter Partes Review (IPR) Proceedings
The United States Patent and Trademark Office (USPTO) continues to handle numerous IPR proceedings, a mechanism allowing third parties to challenge the validity of a patent post-grant. The outcomes of these reviews are critical, as they can lead to the invalidation of patents, affecting industries ranging from pharmaceuticals to technology. Legal professionals should stay abreast of IPR trends and decisions, as they offer insights into patent validity challenges and the evolving standards applied by the USPTO.
These cases highlight the dynamic nature of patent litigation and its far-reaching implications across various industries. Staying informed on these developments is essential for legal professionals navigating the complexities of intellectual property law in 2026.